RMD — ResMed Inc.
Is RMD overbought or oversold? Here is the current MarketMoodz read.
ResMed Inc. (RMD) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $238.19. The rating moved from Overbought to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$238.19
- Last changeMoved from Overbought to Neutral on November 17, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
AI analysis
ResMed Inc. benefits from a leading, defensible position in sleep and home respiratory care with recurring consumable and software revenue streams that support cash flow and product upgrade cycles. Near-term catalysts include continued adoption of connected devices, international market expansion, and cross-sell into rising home‑care trends. Offsetting factors include heightened Medicare program integrity scrutiny that could pressure provider economics, competitive dynamics, potential impacts from broader adoption of weight‑loss pharmacotherapies, and operational risks such as recalls or supply disruptions. Given the company’s established installed base, digital ecosystem and margin profile, the outlook through the next month remains constructive absent material earnings or policy surprises.
Key factors
- Leading global position in sleep-disordered breathing devices and strong brand recognition in CPAP and noninvasive ventilatory care
- High proportion of recurring revenue from device consumables, cloud software and services (patient monitoring, adherence platforms) supporting predictable cash flow
- Large installed base creates cross-sell and upgrade opportunities as new, more connected devices and software offerings are introduced
- Favorable long-term demographic trends (aging population, greater OSA diagnosis rates, increased screening) supporting demand
- Prudent balance sheet and historically solid margins and free cash generation (supports R&D, tuck-in M&A and buybacks/dividends)
- Product cadence and digital health capabilities (remote monitoring, telehealth integration) are differentiators versus smaller competitors
- Distributor and specialty pharmacy channel shifts to chronic injectables and specialty services may create partnership/distribution opportunities for recurring revenue
Risks
- Regulatory and reimbursement pressure from CMS proposals and tighter program integrity (Medicare/Medicaid/MA) could reduce DME reimbursement or increase compliance costs for providers, indirectly pressuring device volumes
- Rising uptake of effective weight‑loss therapies (GLP‑1/amylin combos) may reduce long‑term OSA incidence or severity in some cohorts, lowering CPAP demand over time
- Competition from other medtech vendors, new therapeutic alternatives, or disruptive device innovation could compress pricing or slow share gains
- Product recalls, quality issues or adverse safety events could hurt adoption, revenue and reputation
- Exposure to supply chain or manufacturing disruptions that could delay new product launches or deliveries
- Foreign exchange and international market variability (sales and reimbursement heterogeneity) could weigh on reported growth
- Valuation sensitivity: stock performance could lag if growth disappoints or macro risk‑off persists
Latest MarketMoodz coverage
- Disney outlines three-pillar growth plan: IP, AI, global reach2026-05-06
- Shilling warns of 2026 downturn amid housing stall and capex collapse2026-05-06
- Trump expands pre-deployment AI reviews with Google, Microsoft, xAI2026-05-05
- FBI Warns Banking Spoof Calls Draining Accounts Guidance for Banks and Customers2026-05-05
See today's live rating, score and targets
Members see the live hourly rating for RMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.